title: Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP).
abstract: Preliminary epidemiological and histological studies from Japan suggested that hepatitis C virus (HCV) infection has a role in the development of dilated cardiomyopathy (DCM). This multicenter study was conducted to verify this hypothesis on a large cohort of Italian patients with end-stage heart failure. Antibodies to HCV were determined in the 752 consecutive patients (608 males and 144 females; age, 53 +/- 13 years) who entered the waiting list for cardiac transplantation from 1995 to 1997 at the six cardiac surgery centers participating in the North Italy Transplant program. Three hundred and nine patients (41%) had dilated, 9 (1%) restrictive, and 4 (0.5%) hypertrophic cardiomyopathy; 284 patients (38%) had ischemic, 65 (9%) valvular, and 22 (3%) congenital heart disease; 5 patients (0.5%) had primary pulmonary hypertension; 54 patients (7%) had other or nonspecified heart disease. Overall, 41 of 752 patients (5.4%) resulted anti-HCV-reactive. Serological evidence of HCV infection was found in 12 of 309 patients with DCM (3.9%; 95% CI, 1.7-6.0), and in 29 of 443 without DCM (6.5%; 95% CI, 4.2-8.8), without statistical difference (difference of prevalence rate: 2.6%; 95% CI, -4.9 to 5.8). In conclusion, HCV does not seem to have a primary role in the pathogenesis of DCM. However, since our findings are in disagreement with those obtained in smaller series of patients of other ethnicity, large studies from different countries should be conducted.
authors.affiliation: Centro Trasfusionale e di Immunologia dei Trapianti, IRCCS Ospedale Maggiore, Milano, Italy. dprati@yahoo.com
authors.forename: D
authors.initials: D
authors.lastname: Prati
authors.forename: F
authors.initials: F
authors.lastname: Poli
authors.forename: E
authors.initials: E
authors.lastname: Farma
authors.forename: A
authors.initials: A
authors.lastname: Picone
authors.forename: E
authors.initials: E
authors.lastname: Porta
authors.forename: C
authors.initials: C
authors.lastname: De Mattei
authors.forename: A
authors.initials: A
authors.lastname: Zanella
authors.forename: M
authors.initials: M
authors.lastname: Scalamogna
authors.forename: A
authors.initials: A
authors.lastname: Gamba
authors.forename: E
authors.initials: E
authors.lastname: Gronda
authors.forename: G
authors.initials: G
authors.lastname: Faggian
authors.forename: U
authors.initials: U
authors.lastname: Livi
authors.forename: C
authors.initials: C
authors.lastname: Puricelli
authors.forename: M
authors.initials: M
authors.lastname: Viganò
authors.forename: G
authors.initials: G
authors.lastname: Sirchia
mesh_terms: D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000209:etiology*; D015331:Cohort Studies; D005260:Female; D016027:Heart Transplantation; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence
chemical_list: D018937:Hepatitis C Antibodies